NR3C2 and hydrops fetalis: With regards to medical therapy for HF, 88% of total participants were on angiotensin‐converting enzyme inhibitors/angiotensin II receptor blockers, 91% on beta‐blockers and 54% on mineralocorticoid receptor antagonists.